Hypertensive response with exercise does not increase the prevalence of abnormal Tc-99m SPECT Stress Perfusion Images - 09/08/11
Résumé |
Background |
Systemic hypertension and an exaggerated blood pressure (BP) response with exercise have been associated with ‘false-positive’ findings on stress electrocardiography and echocardiography; however, limited data is available for stress myocardial perfusion imaging (MPI). The purpose of this study was to investigate whether an exaggerated elevation in BP with exercise is associated with an increased prevalence of abnormal MPI.
Methods |
BP responses to exercise were assessed in a cohort of 7,205 patients who underwent stress testing with technetium 99m-SPECT MPI (7/1999-6/2005) for the evaluation of chest pain or dyspnea.
Results |
A hypertensive response, defined as a peak systolic BP≥220 mmHg, occurred in 355 (4.9%) and was not associated with higher rates of ischemic ECG changes (16.1 versus 16.6%; P = .7), differences in Duke treadmill scores (4.7 ± 4 versus 5.1 ± 5; P = .3) or an increased prevalence of abnormal perfusion images (30.1% versus 32.9%; P = .3) to those without a hypertensive exercise response. Patients with a hypertensive response and either intermediate or high-risk MPI (on the basis of summed-difference-scores) referred for coronary angiography, had a high prevalence of coronary artery disease which was similar to those without a hypertensive response (88% versus 83%; P = .5). In an analysis of a community-based patient subset, a hypertensive response was not associated with a difference in either all-cause mortality or subsequent myocardial infarction, coronary revascularization or cardiac death (8% versus 9%; P = .7).
Conclusion |
A hypertensive BP response to exercise is not associated with increased rates of ischemic ECG changes, higher-risk Duke treadmill scores, greater degrees of abnormal MPI or worse clinical outcome.
Le texte complet de cet article est disponible en PDF.Abbreviations : DBP, MPI, SPECT, SBP, SSS, SDS
Plan
Drs Askew, Chareonthaitawee, Miller, and Gibbons have received research grants from Radient Medical; Boston Scientific; Boehringer Ingelheim GmbH; Spectranetics; KAI Pharmaceuticals; TargeGen; Ther Ox; and King Pharmaceuticals. Dr. Gibbons has acted as a consultant for Hawaii Biotech; Cardiovascular Clinical Studies (WOMEN Study); Consumers Union; and Thrombolysis in Myocardial Infarction (TIMI) clinical trials group for TIMI 37A. |
Vol 155 - N° 5
P. 930-937 - mai 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?